<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39433817</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>22</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Losartan and enalapril maleate differently influence SARS-CoV-2-infected vero cells.</ArticleTitle><Pagination><StartPage>24801</StartPage><MedlinePgn>24801</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">24801</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-76657-7</ELocationID><Abstract><AbstractText Label="BACKGROUND">The COVID-19 pandemic has posed significant challenges to global healthcare systems, particularly impacting individuals with pre-existing conditions like hypertension. This study sought to assess the impact of the antihypertensive medications, losartan and enalapril maleate on SARS-CoV-2 infected cells. Vero E6 cells were infected and treated in vitro, evaluating cell viability via the MTT colorimetric assay. Additionally, the study measured relative levels of viral RNA and selected gene messenger RNAs using reverse transcriptase followed by quantitative real-time polymerase chain reaction.</AbstractText><AbstractText Label="RESULTS">The findings revealed that losartan substantially reduced nucleocapsid RNA levels of SARS-CoV-2 to nearly undetectable levels, while enalapril maleate did not demonstrate a significant effect. In response to viral infection, the expression of il-18, p53, p21, and p62 increased compared to uninfected-untreated cells. Notably, il-6 expression was upregulated by both infection and treatments. A comparison between infected cells treated with losartan or enalapril maleate highlighted the presence of distinct profiles in the expression of il-6, p53, p21, and p62.</AbstractText><AbstractText Label="CONCLUSIONS">The data from our study suggest that these medications could interfere with certain effects triggered by SARS-CoV-2 infection in Vero E6 cells. However, their influence appears to vary both quantitatively and qualitatively in the modulation of metabolic and signal transduction pathways.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Majolo</LastName><ForeName>Julia H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Laboratory of Immunology and Microbiology, Pontifical Catholic University of Rio Grande do Sul (PUCRS), Avenida Ipiranga, 6681, Porto Alegre, 90619-900, Rio Grande do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonçalves</LastName><ForeName>João I B</ForeName><Initials>JIB</Initials><AffiliationInfo><Affiliation>Laboratory of Clinical and Experimental Immunology, Pontifical Catholic University of Rio Grande do Sul (PUCRS), Avenida Ipiranga, 6681, Porto Alegre, 90619-900, Rio Grande do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Souza</LastName><ForeName>Renata P</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>Laboratory of Immunology and Microbiology, Pontifical Catholic University of Rio Grande do Sul (PUCRS), Avenida Ipiranga, 6681, Porto Alegre, 90619-900, Rio Grande do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>González</LastName><ForeName>Laura C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Research Center on Molecular and Functional Biology (CPBMF), Pontifical Catholic University of Rio Grande do Sul (PUCRS), Avenida Ipiranga, 6681, Porto Alegre, 90619-900, Rio Grande do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperotto</LastName><ForeName>Nathalia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Research Center on Molecular and Functional Biology (CPBMF), Pontifical Catholic University of Rio Grande do Sul (PUCRS), Avenida Ipiranga, 6681, Porto Alegre, 90619-900, Rio Grande do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silveira</LastName><ForeName>Maiele D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Research Center on Molecular and Functional Biology (CPBMF), Pontifical Catholic University of Rio Grande do Sul (PUCRS), Avenida Ipiranga, 6681, Porto Alegre, 90619-900, Rio Grande do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliveira</LastName><ForeName>Sílvia D</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>Laboratory of Immunology and Microbiology, Pontifical Catholic University of Rio Grande do Sul (PUCRS), Avenida Ipiranga, 6681, Porto Alegre, 90619-900, Rio Grande do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bizarro</LastName><ForeName>Cristiano V</ForeName><Initials>CV</Initials><AffiliationInfo><Affiliation>Research Center on Molecular and Functional Biology (CPBMF), Pontifical Catholic University of Rio Grande do Sul (PUCRS), Avenida Ipiranga, 6681, Porto Alegre, 90619-900, Rio Grande do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Machado</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Research Center on Molecular and Functional Biology (CPBMF), Pontifical Catholic University of Rio Grande do Sul (PUCRS), Avenida Ipiranga, 6681, Porto Alegre, 90619-900, Rio Grande do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basso</LastName><ForeName>Luiz A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Research Center on Molecular and Functional Biology (CPBMF), Pontifical Catholic University of Rio Grande do Sul (PUCRS), Avenida Ipiranga, 6681, Porto Alegre, 90619-900, Rio Grande do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Souza</LastName><ForeName>Ana P D</ForeName><Initials>APD</Initials><AffiliationInfo><Affiliation>Laboratory of Clinical and Experimental Immunology, Pontifical Catholic University of Rio Grande do Sul (PUCRS), Avenida Ipiranga, 6681, Porto Alegre, 90619-900, Rio Grande do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliveira</LastName><ForeName>Jarbas R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Laboratory of Cellular Biophysics and Inflammation, Pontifical Catholic University of Rio Grande do Sul (PUCRS), Avenida Ipiranga, 6681, Porto Alegre, 90619-900, Rio Grande do Sul, Brazil. jarbas@pucrs.br.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferreira</LastName><ForeName>Carlos A S</ForeName><Initials>CAS</Initials><AffiliationInfo><Affiliation>Laboratory of Immunology and Microbiology, Pontifical Catholic University of Rio Grande do Sul (PUCRS), Avenida Ipiranga, 6681, Porto Alegre, 90619-900, Rio Grande do Sul, Brazil. cferreira@pucrs.br.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Finance Code 001</GrantID><Agency>This study was supported in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) - Brasil</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>JMS50MPO89</RegistryNumber><NameOfSubstance UI="D019808">Losartan</NameOfSubstance></Chemical><Chemical><RegistryNumber>69PN84IO1A</RegistryNumber><NameOfSubstance UI="D004656">Enalapril</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019808" MajorTopicYN="Y">Losartan</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004656" MajorTopicYN="Y">Enalapril</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ACEi</Keyword><Keyword MajorTopicYN="N">ARB</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Coronaviruses</Keyword><Keyword MajorTopicYN="N">Hypertension</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>0</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>23</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39433817</ArticleId><ArticleId IdType="pmc">PMC11493994</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-76657-7</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-76657-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bogoch, I. I. et al. Pneumonia of unknown aetiology in Wuhan, China: Potential for international spread via commercial air travel. J. Travel Med. 27, taa008. 10.1093/jtm/taaa008 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7107534</ArticleId><ArticleId IdType="pubmed">31943059</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (WHO). Coronavirus (COVID-19) Dashboard. https://covid19.who.int/ Accessed 6 Feb 2024.</Citation></Reference><Reference><Citation>Yang, X. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir. Med. 8, 475–481. 10.1016/S2213-2600(20)30079-5 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102538</ArticleId><ArticleId IdType="pubmed">32105632</ArticleId></ArticleIdList></Reference><Reference><Citation>Lelapi, N. et al. Cardiovascular disease as a biomarker for an increased risk of COVID-19 infection and related poor prognosis. Biomark. Med. 14, 713–716. 10.2217/bmm-2020-0201 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7236792</ArticleId><ArticleId IdType="pubmed">32426991</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye, Q., Wang, B. &amp; Mao, J. The pathogenesis and treatment of the ''Cytokine storm’ in COVID-19. J. Infect. 80, 607–613. 10.1016/j.jinf.2020.03.037 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7194613</ArticleId><ArticleId IdType="pubmed">32283152</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 579, 270–273. 10.1038/s41586-020-2012-7 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095418</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuzawa, Y., Kimura, K., Ogawa, H. &amp; Tamura, K. Impact of renin–angiotensin–aldosterone system inhibitors on COVID-19. Hypertens. Res. 45, 1147–1153. 10.1038/s41440-022-00922-3 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9113925</ArticleId><ArticleId IdType="pubmed">35581498</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos, R. A. S. et al. Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl. Acad. Sci. USA. 100, 8258–8263. 10.1073/pnas.1432869100 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC166216</ArticleId><ArticleId IdType="pubmed">12829792</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills, K. T., Stefanescu, A. &amp; He, J. The global epidemiology of hypertension. Nat. Rev. Nephrol. 16, 223–237. 10.1038/s41581-019-0244-2 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7998524</ArticleId><ArticleId IdType="pubmed">32024986</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, P. et al. Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ. Res. 126, 1671–1681. 10.1161/CIRCRESAHA.120.317134 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7265882</ArticleId><ArticleId IdType="pubmed">32302265</ArticleId></ArticleIdList></Reference><Reference><Citation>Antunes, K. H. et al. Short-chain fatty acid acetate triggers antiviral response mediated by RIG-I in cells from infants with respiratory syncytial virus bronchiolitis. EBioMedicine. 77, 103891. 10.1016/J.EBIOM.2022.103891 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8871125</ArticleId><ArticleId IdType="pubmed">35220042</ArticleId></ArticleIdList></Reference><Reference><Citation>van Meerloo, J., Kaspers, G. J. L. &amp; Cloos, J. Cell sensitivity assays: The MTT assay. Methods Mol. Biol. 10.1007/978-1-61779-080-5_20 (2011). 731:237 – 45.</Citation><ArticleIdList><ArticleId IdType="pubmed">21516412</ArticleId></ArticleIdList></Reference><Reference><Citation>Marín-Palma, D. et al. Curcumin inhibits in vitro SARS-CoV-2 infection in Vero E6 cells through multiple antiviral mechanisms. Molecules. 26, 6900. 10.3390/molecules26226900 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8618354</ArticleId><ArticleId IdType="pubmed">34833991</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogando, N. S. et al. SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology. J. Gen. Virol. 101, 925–940. 10.1099/jgv.0.001453 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7654748</ArticleId><ArticleId IdType="pubmed">32568027</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmittgen, T. D. &amp; Livak, K. J. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 3, 1101–1108. 10.1038/nprot.2008.73 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18546601</ArticleId></ArticleIdList></Reference><Reference><Citation>Dublin, S. et al. Renin – angiotensin – aldosterone system inhibitors and COVID-19 infection or hospitalization: A cohort study. Am. J. Hypertens. 34, 339–347. 10.1093/ajh/hpaa168 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7665332</ArticleId><ArticleId IdType="pubmed">33048112</ArticleId></ArticleIdList></Reference><Reference><Citation>Flacco, M. E. et al. Treatment with ACE inhibitors or ARBs and risk of severe / lethal COVID-19: A meta- analysis. Heart. 106, 1519–1524. 10.1136/heartjnl-2020-317336 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7371482</ArticleId><ArticleId IdType="pubmed">32611676</ArticleId></ArticleIdList></Reference><Reference><Citation>Dambha-Miller, H. et al. Mortality from angiotensin-converting enzyme-inhibitors and angiotensin receptor blockers in people infected with COVID-19: A cohort study of 3.7 million people. Fam. Pract. 40, 330–337. 10.1093/fampra/cmac094 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9452130</ArticleId><ArticleId IdType="pubmed">36003039</ArticleId></ArticleIdList></Reference><Reference><Citation>Paguio, J. A., Casipit, B. A., John, T. A., Balu, A. &amp; Lo, K. B. Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers and outcomes in hospitalized patients with COVID-19: An updated systematic review and meta-analysis of randomized clinical trials. Expert Rev. Cardiovasc. Ther. 21, 219–226. 10.1080/14779072.2023.2184351 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36821251</ArticleId></ArticleIdList></Reference><Reference><Citation>Peñalvo, J. L. et al. Insights into the association of ACEIs / ARBs use and COVID-19 prognosis: A multistate modelling study of nationwide hospital surveillance data from Belgium. BMJ Open. 11, e053393. 10.1136/bmjopen-2021-053393 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8449849</ArticleId><ArticleId IdType="pubmed">34531225</ArticleId></ArticleIdList></Reference><Reference><Citation>Baral, R. et al. Association between renin-angiotensin-aldosterone system inhibitors and clinical outcomes in patients with COVID-19: A systematic review and Meta-analysis. JAMA Netw. Open. 4, e213594. 10.1001/jamanetworkopen.2021.3594 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8013817</ArticleId><ArticleId IdType="pubmed">33787911</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirjalili, M., Soodejani, M. T., Raadabadi, M., Dehghani, A. &amp; Salemi, F. Does Losartan reduce the severity of COVID-19 in hypertensive patients? BMC Cardiovasc. Disord. 22, 16. 10.1186/s12872-022-02548-2 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8933856</ArticleId><ArticleId IdType="pubmed">35305551</ArticleId></ArticleIdList></Reference><Reference><Citation>Furuhashi, M. et al. Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by Olmesartan, an angiotensin II receptor blocker. Am. J. Hypertens. 28, 15–21. 10.1093/ajh/hpu086 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24842388</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurwitz, D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev. Res. 81, 537–540. 10.1002/ddr.21656 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7228359</ArticleId><ArticleId IdType="pubmed">32129518</ArticleId></ArticleIdList></Reference><Reference><Citation>Nejat, R. et al. Losartan inhibits SARS-CoV-2 replication in vitro. J. Pharm. Pharm. Sci. 24, 390–399. 10.18433/jpps31931 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34319871</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahmani, W. et al. Attenuation of SARS-CoV-2 infection by losartan in human kidney organoids. IScience. 25, 103818. 10.1016/j.isci.2022.103818 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8795780</ArticleId><ArticleId IdType="pubmed">35106453</ArticleId></ArticleIdList></Reference><Reference><Citation>Aziz, M., Fatima, R. &amp; Assaly, R. Elevated interleukin-6 and severe COVID-19: A meta-analysis. J. Med. Virol. 92, 2283–2285. 10.1002/jmv.25948 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7267383</ArticleId><ArticleId IdType="pubmed">32343429</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang, S. et al. SARS-CoV-2 spike protein induces IL-18-mediated cardiopulmonary inflammation via reduced mitophagy. Signal. Transduct. Target. Ther. 8, 108. 10.1038/s41392-023-01368-w (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9998025</ArticleId><ArticleId IdType="pubmed">36894537</ArticleId></ArticleIdList></Reference><Reference><Citation>Broman, N. et al. IL-6 and other biomarkers as predictors of severity in COVID-19. Ann. Med. 53, 410–412. 10.1080/07853890.2020.1840621 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7935117</ArticleId><ArticleId IdType="pubmed">33305624</ArticleId></ArticleIdList></Reference><Reference><Citation>Evangelou, K. et al. Pulmonary infection by SARS-CoV-2 induces senescence accompanied by an inflammatory phenotype in severe COVID-19: Possible implications for viral mutagenesis. Eur. Respir J. 60, 2102951. 10.1183/13993003.02951-2021 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8796696</ArticleId><ArticleId IdType="pubmed">35086840</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardoso, P. R. G. et al. Losartan, but not Enalapril and Valsartan, inhibits the expression of IFN-γ, IL-6, IL-17F and IL-22 in PBMCs from rheumatoid arthritis patients. Open. Rheumatol. J. 12, 160–170. 10.2174/1874312901812010160 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6151964</ArticleId><ArticleId IdType="pubmed">30288187</ArticleId></ArticleIdList></Reference><Reference><Citation>Valente, A. J. et al. Angiotensin II enhances AT 1-Nox1 binding and stimulates arterial smooth muscle cell migration and proliferation through AT 1, Nox1, and interleukin-18. Am. J. Physiol. - Heart Circ. Physiol. 303, 282–296. 10.1152/ajpheart.00231.2012 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3423158</ArticleId><ArticleId IdType="pubmed">22636674</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding, L. H. et al. Enalapril inhibits tubulointerstitial inflammation and NLRP3 inflammasome expression in BSA-overload nephropathy of rats. Acta Pharmacol. Sin. 35, 1293–1301. 10.1038/aps.2014.66 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4186985</ArticleId><ArticleId IdType="pubmed">25152022</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell, G. F. et al. Hemodynamic effects of sacubitril-valsartan versus enalapril in patients with heart failure in the EVALUATE-HF study: Effect modification by left ventricular ejection fraction and sex. Circ. Heart Fail. 14, E007891. 10.1161/CIRCHEARTFAILURE.120.007891 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33663237</ArticleId></ArticleIdList></Reference><Reference><Citation>Panico, K. et al. Cardiac inflammation after ischemia-reperfusion of the kidney: Role of the sympathetic nervous system and the renin-angiotensin system. Cell. Physiol. Biochem. 53, 587–605. 10.33594/000000159 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31535830</ArticleId></ArticleIdList></Reference><Reference><Citation>Su, M. et al. A mini-review on cell cycle regulation of coronavirus infection. Front. Vet. Sci. 7, 586826. 10.3389/fvets.2020.586826 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7674852</ArticleId><ArticleId IdType="pubmed">33251267</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, C. J. &amp; Makin, S. Murine coronavirus replication induces cell cycle arrest in G0/G1 phase. J. Virol. 78, 5658–5669. 10.1128/jvi.78.11.5658-5669.2004 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC415820</ArticleId><ArticleId IdType="pubmed">15140963</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato, Y. &amp; Tsurumi, T. Genome guardian p53 and viral infections. Rev. Med. Virol. 23, 213–220. 10.1002/rmv.1738 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23255396</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, X., Liu, Y., Li, K. &amp; Hao, Z. Roles of p53-mediated host–virus interaction in coronavirus infection. Int. J. Mol. Sci. 24, 6371. 10.3390/ijms24076371 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10094438</ArticleId><ArticleId IdType="pubmed">37047343</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma-Lauer, Y. et al. P53 down-regulates SARS coronavirus replication and is targeted by the SARS-unique domain and PLpro via E3 ubiquitin ligase RCHY1. Proc. Natl. Acad. Sci. USA 113, E5192–E5201 (2016). 10.1073/pnas.1603435113</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5024628</ArticleId><ArticleId IdType="pubmed">27519799</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck, J., Horikawa, I. &amp; Harris, C. Cellular senescence: Mechanisms, morphology, and mouse models. Vet. Pathol. 57, 747–757. 10.1177/0300985820943841 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32744147</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine, A. J. p53, the cellular gatekeeper review for growth and division. Cell. 88, 323–331. 10.1016/S0092-8674(00)81871-1 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9039259</ArticleId></ArticleIdList></Reference><Reference><Citation>Karimian, A., Ahmadi, Y. &amp; Yousefi, B. Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. DNA Repair. 42, 63–71. 10.1016/j.dnarep.2016.04.008 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27156098</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Deiry, W. S. p21(WAF1) mediates cell-cycle inhibition, relevant to cancer suppression and therapy. Cancer Res. 76, 5189–5191. 10.1158/0008-5472.CAN-16-2055 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5028108</ArticleId><ArticleId IdType="pubmed">27635040</ArticleId></ArticleIdList></Reference><Reference><Citation>Engeland, K. Cell cycle regulation: p53-p21-RB signaling. Cell. Death Differ. 29, 946–960. 10.1038/s41418-022-00988-z (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9090780</ArticleId><ArticleId IdType="pubmed">35361964</ArticleId></ArticleIdList></Reference><Reference><Citation>Nag, S., Qin, J., Srivenugopal, K. S., Wang, M. &amp; Zhang, R. The MDM2-p53 pathway revisited. J. Biomed. Res. 27, 254–271. 10.7555/JBR.27.20130030 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3721034</ArticleId><ArticleId IdType="pubmed">23885265</ArticleId></ArticleIdList></Reference><Reference><Citation>Lodi, G. et al. Cell cycle block by p53 activation reduces SARS-CoV-2 release in infected alveolar basal epithelial A549-hACE2 cells. Front. Pharmacol. 13, 1018761. 10.3389/fphar.2022.1018761 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9792496</ArticleId><ArticleId IdType="pubmed">36582523</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar, A., Grams, T. R., Bloom, D. C. &amp; Toth, Z. Signaling pathway reporter screen with SARS-CoV-2 proteins identifies nsp5 as a repressor of p53 activity. Viruses. 14, 1039. 10.3390/v14051039 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9145535</ArticleId><ArticleId IdType="pubmed">35632779</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardozo, C. M. &amp; Hainaut, P. Viral strategies for circumventing p53: The case of severe acute respiratory syndrome coronavirus. Curr. Opin. Oncol. 33, 149–158. 10.1097/CCO.0000000000000713 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7924916</ArticleId><ArticleId IdType="pubmed">33405482</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, W. et al. SARS-CoV-2 N protein induces acute kidney injury via Smad3-Dependent G1 cell cycle arrest mechanism. Adv. Sci. 9, 2103248. 10.1002/advs.202103248 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8787402</ArticleId><ArticleId IdType="pubmed">34813685</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed, S. et al. Apoptosis induced by luteolin in breast cancer: Mechanistic and therapeutic perspectives. Phytomedicine. 59, 152883. 10.1016/j.phymed.2019.152883 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30986716</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng, X., Wang, L. &amp; Li, Y. Change of telomere length in angiotensin II-induced human glomerular mesangial cell senescence and the protective role of losartan. Mol. Med. Rep. 4, 255–260. 10.3892/mmr.2011.436 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21468560</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi, Y., Bowman, J. W. &amp; Jung, J. U. Autophagy during viral infection - A double-edged sword. Nat. Rev. Microbiol. 16, 341–354. 10.1038/s41579-018-0003-6 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6907743</ArticleId><ArticleId IdType="pubmed">29556036</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu, Y. et al. ORF3a-mediated incomplete autophagy facilitates severe acute respiratory syndrome coronavirus-2 replication. Front. Cell. Dev. Biol. 9, 716208. 10.3389/fcell.2021.716208 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8353283</ArticleId><ArticleId IdType="pubmed">34386498</ArticleId></ArticleIdList></Reference><Reference><Citation>Moscat, J. &amp; Diaz-Meco, M. T. p62 at the crossroads of autophagy, apoptosis, and cancer. Cell. 137, 1001–1004. 10.1016/j.cell.2009.05.023 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3971861</ArticleId><ArticleId IdType="pubmed">19524504</ArticleId></ArticleIdList></Reference><Reference><Citation>Zambalde, É. P. et al. Increased mTOR signaling and impaired autophagic flux are hallmarks of SARS-CoV-2 infection. Curr. Issues Mol. Biol. 45, 327–336. 10.3390/cimb45010023 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9858158</ArticleId><ArticleId IdType="pubmed">36661509</ArticleId></ArticleIdList></Reference><Reference><Citation>Koči, J., Novotová, M., Sláviková, M., Klempa, B. &amp; Zahradník, I. SARS-CoV-2 exploits non-canonical autophagic processes to replicate, mature, and Egress the infected Vero E6 cells. Pathogens. 11, 1535. 10.3390/pathogens11121535 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9781122</ArticleId><ArticleId IdType="pubmed">36558869</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, N., Shibata, Y., Paulo, J. A., Gygi, S. P. &amp; Rapopor, T. A. A conserved membrane curvature-generating protein is crucial for autophagosome formation in fission yeast. Nat. Commun. 14, 4765. 10.1038/s41467-023-40530-4 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10409813</ArticleId><ArticleId IdType="pubmed">37553386</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang, C. et al. Inhibition of autophagy suppresses SARS-CoV-2 replication and ameliorates pneumonia in hACE2 transgenic mice and xenografted human lung tissues. J. Virol. 95, e01537–e01521. 10.1128/JVI.01537-21 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8610582</ArticleId><ArticleId IdType="pubmed">34550769</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding, S. et al. IL-8 is involved in estrogen-related receptor α-regulated proliferation and migration of colorectal cancer cells. Dig. Dis. Sci. 62, 3438–3446. 10.1007/s10620-017-4779-4 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28993941</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv, G., Zhu, G., Xu, M., Gao, X. &amp; Xiao, Q. Inhibition of carrageenan-induced dental inflammatory responses owing to decreased TRPV1 activity by dexmedetomidine. J. Inflamm. 17, 18. 10.1186/s12950-020-00245-5 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7195724</ArticleId><ArticleId IdType="pubmed">32377171</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa, B. P. et al. Fructose-1,6-bisphosphate induces generation of reactive oxygen species and activation of p53-dependent cell death in human endometrial cancer cells. J. Appl. Toxicol. 41, 1050–1062. 10.1002/jat.4091 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33078453</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa, B. P. et al. Methoxyeugenol regulates the p53/p21 pathway and suppresses human endometrial cancer cell proliferation. J. Ethnopharmacol. 267, 113645. 10.1016/j.jep.2020.113645 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33271245</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, T. et al. Aggravation of acute kidney injury by mPGES-2 down regulation is associated with autophagy inhibition and enhanced apoptosis. Sci. Rep. 7, 10247 (2017). 10.1038/s41598-017-10271-8 (erratum in: Sci Rep. 2018; 8:17228. 10.1038/s41598-018-35440-1).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5579259</ArticleId><ArticleId IdType="pubmed">28860615</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, J. S. et al. Prognostic significance of LC3B and p62/SQSTM1 expression in gastric adenocarcinoma. Anticancer Res. 39, 6711–6722. 10.21873/anticanres.13886 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31810936</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>